Inactive Instrument

Horizon Therapeutics Public Limited Company Stock price

Equities

HZNP

IE00BQPVQZ61

Pharmaceuticals

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 08-05-31
Director of Finance/CFO 41 16-03-31
Chief Tech/Sci/R&D Officer 49 18-05-31
Members of the board TitleAgeSince
Chief Executive Officer 57 08-05-31
More insiders
Horizon Therapeutics plc is an Ireland-based global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.
More about the company
  1. Stock
  2. Equities
  3. Stock Horizon Therapeutics Public Limited Company - Nasdaq